During the same period, a total of 85 men were identified from the 5% "non-cancer control" sample as having a Medicare claims diagnosis of incident prostate cancer and receiving a GnRH agonist within a year of diagnosis after excluding men that may not have been registered in SEER due to methodologic issues. This evidence concerns the gene GNRH1 and prostate carcinoma.